Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab in active early rheumatoid arthritis.

F C Breedveld1, P Emery, E Keystone

  • 1Department of Rheumatology, University of Leiden, Leiden, The Netherlands. f.c.breedveld@lumc.nl

Annals of the Rheumatic Diseases
|January 15, 2004
PubMed
Summary

Infliximab plus methotrexate significantly reduced structural damage progression in early rheumatoid arthritis (RA) patients over two years. Early infliximab treatment may offer long-term benefits by preventing joint damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.

Arthritis research & therapy·2025
Same author

The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).

Clinical rheumatology·2019
Same author

Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.

Journal of scleroderma and related disorders·2018
Same author

Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.

Atherosclerosis·2018
Same author

Secular trends in the impact factors of SLE publications over a 45-year period-a systematic review.

Lupus·2018
Same author

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Scandinavian journal of rheumatology·2017

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Early rheumatoid arthritis (RA) is characterized by active joint inflammation and progressive structural damage.
  • Methotrexate (MTX) is a cornerstone therapy, but some patients experience persistent disease activity.
  • The combination of biologics with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) is a common strategy to improve outcomes.

Purpose of the Study:

  • To evaluate the efficacy of infliximab combined with methotrexate (MTX) in inhibiting structural damage progression in early rheumatoid arthritis (RA).
  • To assess the impact of early intervention with infliximab on radiographic progression in patients with active RA despite MTX therapy.

Main Methods:

  • Subanalysis of the Anti-TNF Therapy in RA with Concomitant Therapy (ATTRACT) study data.

Related Experiment Videos

  • Inclusion of 428 patients with active RA despite MTX, with 82 classified as early RA (disease duration ≤ 3 years).
  • Comparison of structural damage progression (modified van der Heijde-Sharp score) over 102 weeks between MTX-only and infliximab plus MTX groups.

    • Main Results:

    • Infliximab plus MTX significantly reduced erosion and joint space narrowing scores compared to MTX-only in early RA patients.
    • This benefit was observed consistently in both hand and foot joints.
    • Significant inhibition of structural damage progression was noted across all evaluated infliximab dosage regimens.

    Conclusions:

    • Combination therapy with infliximab and MTX effectively inhibited structural damage progression in early RA over a 2-year period.
    • Early introduction of infliximab in RA patients with active disease despite MTX may lead to long-term benefits.
    • Preventing radiographic progression and preserving joint integrity are key advantages of early infliximab intervention.